Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease Jacoline C. BouvyPall JonssonJohn Gallacher Current Opinion Open access 22 November 2018 Pages: 1085 - 1090
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies Juliane GustAgne TaraseviciuteCameron J. Turtle Leading Article 01 November 2018 Pages: 1091 - 1101
Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis Pierre EllulRichard DelormeSamuele Cortese Systematic Review 20 September 2018 Pages: 1103 - 1112
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms Maira Aguiar WerneckGuilherme Trevizan KortasJoão Mauricio Castaldelli-Maia Systematic Review 25 October 2018 Pages: 1113 - 1129
VMAT2 Inhibitors in Neuropsychiatric Disorders Arjun TarakadJoohi Jimenez-Shahed Review Article 10 October 2018 Pages: 1131 - 1144
Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis Marita ZimmermannElizabeth BrouwerJosh J. Carlson Original Research Article 23 August 2018 Pages: 1145 - 1157
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential Alexander KlistornerYi ChaiRENEW MF-VEP Investigators Original Research Article Open access 28 September 2018 Pages: 1159 - 1171
Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis Mark GudesblattKarl WissemannLily Lee Original Research Article Open access 24 August 2018 Pages: 1173 - 1181
Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis Mark GudesblattKarl WissemannLily Lee Correction 22 September 2018 Pages: 1183 - 1183
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain John A. HeyPetr KocisMartin Tolar Correction 12 November 2018 Pages: 1185 - 1185